Literature DB >> 31285675

Clinical experience of patients referred to a multidisciplinary cardio-oncology clinic: an observational cohort study.

C Kappel1, M Rushton2, C Johnson3, O Aseyev4, G Small3, A Law3, J Ivars5, S Dent6.   

Abstract

Introduction: Cardiovascular disease is the 2nd leading cause of long-term morbidity and mortality in cancer survivors. Cardio-oncology clinics (cocs) have emerged to address the issue; however, there is a paucity of data about the demographics and clinical outcomes of patients seen in the coc setting.
Methods: Cancer patients referred to The Ottawa Hospital coc were included in this retrospective observational study. Data collected were patient demographics, cancer type and stage, reason for referral, cardiac risk factors, cardiac assessments and treatment, and clinical outcomes.
Results: Between 2008 and 2015, 779 patients (516 women, 66%; 263 men, 34%) were referred to the coc. Median age of the patients at cancer diagnosis was 60 years (range: 18-90 years). The most frequent reasons for referral were decreased left ventricular ejection fraction (33%), pre-chemotherapy assessment (14%), and arrhythmia (14%). Treatment with cardiac medication was given in 322 patients (41%), 181 (56%) of whom received more than 2 cardiac medications, with 57 (18%) receiving an angiotensin-converting enzyme inhibitor (acei), 46 (14%) receiving an acei and a beta-blocker, and 38 (12%) receiving a beta-blocker. Of 163 breast cancer patients, 129 (79%) were able to complete targeted therapy with coc co-management. Most of the 779 patients (n = 643, 83%) were alive at the time of the last data collection. Conclusions: This cohort study is one of the largest to report characteristics and clinical outcomes of patients referred to a coc. Collaboration between oncologists and cardiologists resulted in completion of cancer therapy in most patients. Ongoing analysis of referral patterns, management plans, and patient outcomes will help to guide the cardiac care of oncology patients, ultimately optimizing cancer and cardiac outcomes alike.

Entities:  

Keywords:  Cardio-oncology; cardiac outcomes; cardiotoxicity; lvef; targeted therapy

Year:  2019        PMID: 31285675      PMCID: PMC6588054          DOI: 10.3747/co.26.4509

Source DB:  PubMed          Journal:  Curr Oncol        ISSN: 1198-0052            Impact factor:   3.677


  16 in total

Review 1.  Burgeoning Cardio-Oncology Programs: Challenges and Opportunities for Early Career Cardiologists/Faculty Directors.

Authors:  Tochi M Okwuosa; Ana Barac
Journal:  J Am Coll Cardiol       Date:  2015-09-08       Impact factor: 24.094

2.  Pembrolizumab plus Chemotherapy in Metastatic Non-Small-Cell Lung Cancer.

Authors:  Leena Gandhi; Delvys Rodríguez-Abreu; Shirish Gadgeel; Emilio Esteban; Enriqueta Felip; Flávia De Angelis; Manuel Domine; Philip Clingan; Maximilian J Hochmair; Steven F Powell; Susanna Y-S Cheng; Helge G Bischoff; Nir Peled; Francesco Grossi; Ross R Jennens; Martin Reck; Rina Hui; Edward B Garon; Michael Boyer; Belén Rubio-Viqueira; Silvia Novello; Takayasu Kurata; Jhanelle E Gray; John Vida; Ziwen Wei; Jing Yang; Harry Raftopoulos; M Catherine Pietanza; Marina C Garassino
Journal:  N Engl J Med       Date:  2018-04-16       Impact factor: 91.245

3.  Prevention and Monitoring of Cardiac Dysfunction in Survivors of Adult Cancers: American Society of Clinical Oncology Clinical Practice Guideline Summary.

Authors:  Saro H Armenian; Christina Lacchetti; Daniel Lenihan
Journal:  J Oncol Pract       Date:  2016-12-06       Impact factor: 3.840

Review 4.  Trastuzumab containing regimens for early breast cancer.

Authors:  Lorenzo Moja; Ludovica Tagliabue; Sara Balduzzi; Elena Parmelli; Vanna Pistotti; Valentina Guarneri; Roberto D'Amico
Journal:  Cochrane Database Syst Rev       Date:  2012-04-18

5.  Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma.

Authors:  Jedd D Wolchok; Vanna Chiarion-Sileni; Rene Gonzalez; Piotr Rutkowski; Jean-Jacques Grob; C Lance Cowey; Christopher D Lao; John Wagstaff; Dirk Schadendorf; Pier F Ferrucci; Michael Smylie; Reinhard Dummer; Andrew Hill; David Hogg; John Haanen; Matteo S Carlino; Oliver Bechter; Michele Maio; Ivan Marquez-Rodas; Massimo Guidoboni; Grant McArthur; Celeste Lebbé; Paolo A Ascierto; Georgina V Long; Jonathan Cebon; Jeffrey Sosman; Michael A Postow; Margaret K Callahan; Dana Walker; Linda Rollin; Rafia Bhore; F Stephen Hodi; James Larkin
Journal:  N Engl J Med       Date:  2017-09-11       Impact factor: 91.245

6.  Anticipating the "Silver Tsunami": Prevalence Trajectories and Comorbidity Burden among Older Cancer Survivors in the United States.

Authors:  Shirley M Bluethmann; Angela B Mariotto; Julia H Rowland
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2016-07       Impact factor: 4.254

Review 7.  Evaluation and management of patients with heart disease and cancer: cardio-oncology.

Authors:  Joerg Herrmann; Amir Lerman; Nicole P Sandhu; Hector R Villarraga; Sharon L Mulvagh; Manish Kohli
Journal:  Mayo Clin Proc       Date:  2014-09       Impact factor: 7.616

Review 8.  Anthracycline Chemotherapy and Cardiotoxicity.

Authors:  John V McGowan; Robin Chung; Angshuman Maulik; Izabela Piotrowska; J Malcolm Walker; Derek M Yellon
Journal:  Cardiovasc Drugs Ther       Date:  2017-02       Impact factor: 3.727

Review 9.  Modern-day cardio-oncology: a report from the 'Heart Failure and World Congress on Acute Heart Failure 2018'.

Authors:  Markus S Anker; Alessia Lena; Sara Hadzibegovic; Yury Belenkov; Jutta Bergler-Klein; Rudolf A de Boer; Alain Cohen-Solal; Dimitrios Farmakis; Stephan von Haehling; Teresa López-Fernández; Radek Pudil; Thomas Suter; Carlo G Tocchetti; Alexander R Lyon
Journal:  ESC Heart Fail       Date:  2018-12

Review 10.  Cardiotoxicity of Anticancer Therapeutics.

Authors:  Jerry Dong; Hong Chen
Journal:  Front Cardiovasc Med       Date:  2018-02-07
View more
  8 in total

Review 1.  Cardio-Oncology Education and Training: JACC Council Perspectives.

Authors:  Jose A Alvarez-Cardona; Jordan Ray; Joseph Carver; Vlad Zaha; Richard Cheng; Eric Yang; Joshua D Mitchell; Keith Stockerl-Goldstein; Lavanya Kondapalli; Susan Dent; Anita Arnold; Sherry Ann Brown; Monica Leja; Ana Barac; Daniel J Lenihan; Joerg Herrmann
Journal:  J Am Coll Cardiol       Date:  2020-11-10       Impact factor: 24.094

Review 2.  Association between pre-pregnancy multimorbidity and adverse maternal outcomes: A systematic review.

Authors:  Hilary K Brown; Anthony McKnight; Amira Aker
Journal:  J Multimorb Comorb       Date:  2022-04-30

3.  A virtual-hybrid approach to launching a cardio-oncology clinic during a pandemic.

Authors:  Sherry-Ann Brown; Sahishnu Patel; David Rayan; Svetlana Zaharova; Mingqian Lin; Tarek Nafee; Bipin Sunkara; Ragasnehith Maddula; James MacLeod; Krishna Doshi; Joshua Meskin; David Marks; Jorge Saucedo
Journal:  Cardiooncology       Date:  2021-01-13

4.  Capecitabine-mediated heart failure in colorectal cancer: a case series.

Authors:  Erin N McAndrew; Davinder S Jassal; Benjamin A Goldenberg; Christina A Kim
Journal:  Eur Heart J Case Rep       Date:  2021-03-02

5.  A Population-Based Study of Cardiovascular Disease Mortality in Italian Cancer Patients.

Authors:  Lucia Mangone; Pamela Mancuso; Luigi Tarantini; Mario Larocca; Isabella Bisceglia; Angela Damato; Paolo Giorgi Rossi; Alessandro Navazio; Carmine Pinto
Journal:  Cancers (Basel)       Date:  2021-11-24       Impact factor: 6.639

Review 6.  Pursuing Connectivity in Cardio-Oncology Care-The Future of Telemedicine and Artificial Intelligence in Providing Equity and Access to Rural Communities.

Authors:  Coralea Kappel; Moira Rushton-Marovac; Darryl Leong; Susan Dent
Journal:  Front Cardiovasc Med       Date:  2022-06-13

7.  Cardiovascular drug interventions in the cardio-oncology clinic by a cardiology pharmacist: ICOP-Pharm study.

Authors:  Israa Fadhil Yaseen; Hasan Ali Farhan
Journal:  Front Cardiovasc Med       Date:  2022-09-29

Review 8.  Cardiac Biomarkers in Patients with Cancer: Considerations, Clinical Implications, and Future Avenues.

Authors:  Valentina Bracun; Joseph Pierre Aboumsallem; Peter van der Meer; Rudolf A de Boer
Journal:  Curr Oncol Rep       Date:  2020-06-09       Impact factor: 5.075

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.